Clinical Trial

A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients

Study acronym: Pan HER2
Recruiting
View on ClinicalTrials.gov →
Summary
This is a multicenter, non-interventional, descriptive study to retrospectively collect solid tumor samples from focused tumor types (NSCLC, GYN cancers, BTC and UC) and assess both assay concordance and interpretation concordance.
Protocol Amendment History 1 change
notable Trial sites expanded: 11 -> 14 locations 2026-04-23
Trial Details
NCT Number NCT07404202
Lead Sponsor AstraZeneca
Conditions Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
Enrollment 2,100 participants
Start Date 2026-03-06
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11